Today: 2 July 2026
Browse Category

NYSE:LLY 10 December 2025 - 20 December 2025

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Dec. 20, 2025 — Eli Lilly and Company is closing out 2025 with momentum—and with fresh headlines that underscore why Eli Lilly stock has become one of the market’s most closely watched healthcare names. Shares last closed at $1,071.44 after trading between $1,059.01 and $1,075.38, keeping the stock within reach of its recent highs. Stock Analysis The bigger story isn’t just the price. Lilly entered the rarefied “$1 trillion market value” club this year—an inflection point for a pharmaceutical company—and it’s doing so on the back of a rapidly expanding obesity and cardiometabolic franchise, a pipeline packed with next-generation candidates, and a policy environment that is increasingly forcing drugmakers to prove they can grow volume even as prices face pressure. Reuters+1
20 December 2025
···
Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly and Company ended Friday, December 19, 2025, with a solid gain, then barely budged in after-hours trading—an important clue about how investors are digesting the latest wave of obesity-drug headlines heading into next week. One key calendar note up front: U.S. stock markets do not open on Saturdays. With December 19 falling on a Friday, the next regular stock-market open is Monday, December 22, 2025.
20 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly and Company finished Thursday’s session higher and held those gains in after-hours trading, as investors digested fresh late-stage data for its oral obesity candidate orforglipron—and weighed a second, potentially market-moving theme: pricing pressure and affordability initiatives. As of early evening after the closing bell, LLY was little changed in after-hours trading at $1,057.26, after closing the regular session at $1,056.88. Investing.com
18 December 2025
···
Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

Eli Lilly (LLY) Stock News Today: Orforglipron Pill Data, Pricing Moves, and Wall Street Forecasts for 2026

December 18, 2025 — Eli Lilly and Company is back in the spotlight after the drugmaker released new Phase 3 results for its experimental oral obesity medicine orforglipron, a development investors have been watching closely as the weight-loss market pushes beyond injections and into pills. At the same time, a report said Lilly is preparing material price cuts in Canada for its blockbuster medicines Mounjaro and Zepbound—a reminder that pricing and access remain central to the long-term investment case. Reuters+2Reuters+2 LLY shares were trading around $1,060 on Thursday, December 18, up about 1.75% on the session at the time of the latest available trade, after moving between roughly $1,036 and $1,079 intraday.
18 December 2025
··
Eli Lilly Stock (LLY) After Hours Dec. 17, 2025: Latest Price, Today’s Headlines, and What to Watch Before Thursday’s Open

Eli Lilly Stock (LLY) After Hours Dec. 17, 2025: Latest Price, Today’s Headlines, and What to Watch Before Thursday’s Open

Dec. 17, 2025 — Eli Lilly and Company finished Wednesday lower and then held steady in extended trading, as investors balanced a risk-off day for equities with fresh headlines on U.S. drug-pricing negotiations, ongoing “rotation” trades favoring healthcare, and new collaboration news tied to next-generation obesity therapeutics. As of 4:31 p.m. ET, LLY was trading around $1,041.79 in after-hours action, essentially unchanged from where it ended the regular session. StockAnalysis
17 December 2025
··
Eli Lilly Stock News Today (Dec. 17, 2025): LLY Holds Near Record Highs as Analysts Lift Targets and Obesity Pipeline Momentum Builds

Eli Lilly Stock News Today (Dec. 17, 2025): LLY Holds Near Record Highs as Analysts Lift Targets and Obesity Pipeline Momentum Builds

Eli Lilly and Company stock traded in the mid-$1,050s in U.S. session Wednesday, December 17, 2025, hovering near recent highs as investors weighed fresh analyst commentary and new partnership headlines against an already-strong run for the pharma giant. In early trading, LLY was modestly higher, with the session range spanning roughly $1,051 to $1,064. The near-term story for Eli Lilly stock remains dominated by one theme: sustained demand for its GLP-1/“incretin” portfolio. But the market is also increasingly focused on what comes next—especially the oral obesity candidate orforglipron and the next-wave injectable retatrutide—because those products are central to whether Lilly can justify a valuation that has pushed toward the trillion-dollar milestone. Reuters+2Reuters+2
17 December 2025
·
Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly and Company stock remains one of the market’s most closely watched healthcare names as 2025 winds down—powered by blockbuster demand for obesity and diabetes medicines, and increasingly driven by what comes next: faster, deeper weight loss therapies, an oral GLP-1 pipeline, and a manufacturing expansion designed to keep up with demand. In early trading on Tuesday, Dec. 16, Eli Lilly shares hovered around the $1,050 area, after a year that included the company becoming the first drugmaker to reach a $1 trillion market value—a milestone that underscored how central Lilly’s metabolic franchise has become to investors. StockAnalysis+1
16 December 2025
··
Eli Lilly Stock (LLY) After Hours Today: What to Know Before the Market Opens Tuesday, Dec. 16, 2025

Eli Lilly Stock (LLY) After Hours Today: What to Know Before the Market Opens Tuesday, Dec. 16, 2025

Eli Lilly and Company ended Monday’s session with a strong gain, and the stock was largely steady in after-hours trading—an important “temperature check” for investors heading into Tuesday’s open. As the market digests fresh headlines across obesity drugs, regulation, and litigation, Lilly remains one of the most closely watched names in healthcare—and one of the most influential stocks in major indexes. Here’s a detailed, news-driven look at what moved LLY today, what’s crossing the tape after the bell, and what matters most before the opening bell tomorrow.
15 December 2025
·
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

December 15, 2025 — Eli Lilly and Company stock is starting the new week in focus as investors weigh a rapid-fire set of catalysts: a headline-grabbing Phase 3 result for next‑generation obesity drug retatrutide, fresh scrutiny around the FDA review timeline for oral GLP‑1 candidate orforglipron, ongoing capacity expansion in the U.S., and a notable analyst price-target tweak hitting the tape today. MarketBeat+3Reuters+3Reuters+3 Below is what’s moving Eli Lilly stock as of 15.12.2025, what the latest forecasts imply, and which risks matter most heading into 2026.
15 December 2025
··
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Updated: December 14, 2025 Eli Lilly and Company heads into the new week with investors focused on one big theme: how far the company can extend its lead in obesity and cardiometabolic medicine while scaling supply and navigating pricing pressure. The stock’s most recent close was $1,027.51. StockAnalysis
14 December 2025
··
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Updated: December 14, 2025Coverage window for this report: December 8–14, 2025 Wall Street heads into the week of Dec. 15, 2025 with U.S. healthcare and pharma mega-caps back in the spotlight—pulled by three powerful forces that all intensified in the last seven days: the obesity-drug arms race, Washington’s policy crosscurrents around insurance subsidies and PBM transparency, and a faster-moving FDA that is simultaneously accelerating reviews and reopening safety scrutiny in sensitive pediatric categories. Reuters+3Reuters+3Reuters+3
14 December 2025
······
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Updated: December 12, 2025Company: Eli Lilly and CompanyStock price: $1,027.51 MarketWatch Eli Lilly stock closed the week at $1,027.51 after a late-week rally, outperforming a softer broader market session on Friday. MarketWatch The catalyst mix was familiar—but still powerful: blockbuster momentum in obesity/diabetes, fresh late-stage data that raises the bar for next-generation weight loss drugs, and a steady stream of regulatory and access headlines that keep Lilly’s pipeline and pricing strategy in the spotlight.
13 December 2025
···
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up a decision on Lilly’s oral obesity pill, and late-stage oncology data presented at a major medical meeting. After the bell: LLY finished the regular session at $1,027.51 and traded in a tight range in the first part of the after-hours session, hovering near $1,028–$1,029. MarketWatch+2StockAnalysis+2
12 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for its GLP‑1 franchise. As of Thursday’s close, Eli Lilly shares were trading around $1,006, up roughly 1–1.5% on the day, after swinging between an intraday high above $1,030 and a low just under $990.Investing.com+1 Late in the session and into after‑hours trading, the stock hovered slightly above the close near $1,009, according to real‑time data. The move leaves LLY only a few percentage points below its recent all‑time high around $1,110 and up more than 30% year‑to‑date, even after a sharp pullback in late November.TradingView+1
11 December 2025
···
Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

On November 21, 2025, Eli Lilly and Company became the first pharmaceutical group ever to cross a $1 trillion market value, lifted by surging demand for its obesity and diabetes drugs Mounjaro and Zepbound.Reuters+2Financial Times+2 Since then, investors have been digesting that historic moment alongside a fresh wave of drug data, a multibillion‑dollar manufacturing build‑out in Alabama, and a drumbeat of new analyst forecasts. Here’s a detailed, news‑driven look at where Eli Lilly stock stands today and what the latest information since 11/21/2025 suggests about its 2026 outlook.
11 December 2025
··
Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

The U.S. stock market is ending 2025 near record highs, but today’s tape is choppy: a fresh Federal Reserve rate cut is colliding with worries that AI spending is turning into a bubble.Reuters+1 Against that backdrop, investors are asking a familiar question: what are the best stocks to buy now in the U.S. market? Below is a news‑driven, research‑heavy look at eight U.S. stocks that many analysts and institutions see as compelling ideas to research in December 2025.
11 December 2025
········
Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly and Company closed just under the psychologically important $1,000 mark on Wednesday, December 10, 2025, then ticked slightly higher in after‑hours trading as investors digested a wave of company‑specific news against a backdrop of a fresh Federal Reserve rate cut.Yahoo Finance+1 Below is what happened after the bell on Dec. 10 and what traders and long‑term investors should know before the market opens on Dec. 11, 2025.
11 December 2025
··
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Updated: December 10, 2025 As of mid‑day trading on December 10, 2025, Eli Lilly is changing hands at around $980 per share, down slightly on the day and just below its recent all‑time high above $1,050. That price values Lilly at roughly $930–$1,000+ billion in market cap, depending on intraday moves, placing it in the same league as mega‑cap tech giants and making it the first healthcare company ever to cross the $1 trillion mark. Reuters
10 December 2025
··
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax Société Anonyme is back in the spotlight on December 10, 2025, after its share price spiked again on fresh takeover speculation involving U.S. pharma giant Eli Lilly. The move caps an extraordinary year in which the French biotech has transformed from a relatively obscure name into a multibillion‑euro inflammatory bowel disease contender.Reuters+1 Below is a detailed rundown of today’s news, the fundamental drivers, and the latest forecasts and analyses being published about Abivax.
10 December 2025
····
1 … 7 8 9 10 11 … 13

Stock Market Today

  • Haleon CFO Dawn Allen Gets Share Award, Sells Part to Pay Tax
    July 2, 2026, 10:30 AM EDT. Haleon PLC (LSE/NYSE: HLN) said CFO Dawn Allen was given a Performance Share Plan award that vests June 30, 2026. She got 283,193 shares under the 2024 plan, based on targets through December 2025. Allen sold 133,301 shares at £3.52 each in London to cover taxes owed from the vesting. Shares include dividends and are subject to malus and clawback. The company made the disclosure under UK rules and reminded that execs have to hold shares for two years after they vest. Details will be in next year's annual report and 20-F.
Go toTop